About Enhancer
| Enhancer ID: | E_01_0960 |
| Species: | human |
| Position : | chr11:33856049-33858049   |
| Biosample name: | |
| Experiment class : | High+Lowthroughput |
| Enhancer type: | Enhancer |
| Disease: | Leukemia |
| Pubmed ID: | 32632335 |
| Enhancer experiment: | RNA-seq,ChIPseq |
| Enhancer experiment description: | For example, cis-X identified both ABTB2 and TMEM38B as cis-activated by structural variants; however, both genes were adjacent to known proto-oncogenes in the same TAD (LMO2 and TAL2, respectively); thus, they were potentially coregu_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x0002_lated by an aberrant enhancer. |
About Target gene
| Target gene : | LMO2(Rbtn-2,Rbtn2,Rhom-2,Ttg2),TAL2 |
| Strong evidence: | qRT-PCR,qPCR,ChIP,3C |
| Less strong evidence: | RNA-Seq |
| Target gene experiment description: | For example, cis-X identified both ABTB2 and TMEM38B as cis-activated by structural variants; however, both genes were adjacent to known proto-oncogenes in the same TAD (LMO2 and TAL2, respectively); thus, they were potentially coregu_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x0002_lated by an aberrant enhancer.;For example, cis-X identified both ABTB2 and TMEM38B as cis-activated by structural variants; however, both genes were adjacent to known proto-oncogenes in the same TAD (LMO2 and TAL2, respectively); thus, they were potentially coregu_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x0002_lated by an aberrant enhancer. |
About TF
| TF name : | -- |
| TF experiment: | RNA-seq,ChIPseq |
| TF experiment description: | For example, cis-X identified both ABTB2 and TMEM38B as cis-activated by structural variants; however, both genes were adjacent to known proto-oncogenes in the same TAD (LMO2 and TAL2, respectively); thus, they were potentially coregu_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x0002_lated by an aberrant enhancer.;For example, cis-X identified both ABTB2 and TMEM38B as cis-activated by structural variants; however, both genes were adjacent to known proto-oncogenes in the same TAD (LMO2 and TAL2, respectively); thus, they were potentially coregu_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x0002_lated by an aberrant enhancer. |
About Function
| Enhancer function : | For example, cis-X identified both ABTB2 and TMEM38B as cis-activated by structural variants; however, both genes were adjacent to known proto-oncogenes in the same TAD (LMO2 and TAL2, respectively); thus, they were potentially coregu_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x0002_lated by an aberrant enhancer. |
| Enhancer function experiment: | Immunohistochemical staining |
| Enhancer function experiment description: |
For example, cis-X identified both ABTB2 and TMEM38B as cis-activated by structural variants; however, both genes were adjacent to known proto-oncogenes in the same TAD (LMO2 and TAL2, respectively); thus, they were potentially coregu_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x0002_lated by an aberrant enhancer. |
About SNP
| SNP ID: | -- |
Upstream Pathway Annotation of TF
| GeneName | Pathway Name | Source | Gene Number |
|---|
Enhancer associated network
The number on yellow line represents the distance between enhancer and
target gene